Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy:a multicenter prospective 8 years follow up study

Sasso, Ferdinando Carlo, Lascar, Nadia, Ascione, Antonella, Carbonara, Ornella, de Nicola, Luca, Minutolo, Roberto, Salvatore, Teresa, Rizzo, Maria Rosaria, Cirillo, Plinio, Paolisso, Giuseppe, Marfella, Raffaele and on behalf of NID-2 study group (2016). Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy:a multicenter prospective 8 years follow up study. Cardiovascular Diabetology, 15 (1),

Abstract

Background: Although numerous studies and metanalysis have shown the beneficial effect of statin therapy in CVD secondary prevention, there is still controversy such the use of statins for primary CVD prevention in patients with DM. The purpose of this study was to evaluate the occurrence of total major adverse cardio-vascular events (MACE) in a cohort of patients with type 2 diabetes complicated by nephropathy treated with statins, in order to verify real life effect of statin on CVD primary prevention. Methods: We conducted an observational prospective multicenter study on 564 patients with type 2 diabetic nephropathy free of cardiovascular disease attending 21 national outpatient diabetes clinics and followed them up for 8 years. 169 of them were treated with statins (group A) while 395 were not on statins (group B). Results: Notably, none of the patients was treated with a high-intensity statin therapy according to last ADA position statement. Total MACE occurred in 32 patients from group A and in 68 patients from group B. Fatal MACE occurred in 13 patients from group A and in 30 from group B; nonfatal MACE occurred in 19 patients from group A and in 38 patients from group B. The analysis of the Kaplan-Meier survival curves showed a not statistically significant difference in the incidence of total (p 0.758), fatal (p 0.474) and nonfatal (p 0.812) MACE between the two groups. HbA1c only showed a significant difference in the incidence of MACE between the two groups (HR 1.201, CI 1.041-1.387, p 0.012). Conclusions: These findings suggest that, in a real clinical setting, moderate-intensity statin treatment is ineffective in cardiovascular primary prevention for patients with diabetic nephropathy.

Publication DOI: https://doi.org/10.1186/s12933-016-0463-9
Divisions: Life & Health Sciences
Life & Health Sciences > Biosciences
Additional Information: © 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Uncontrolled Keywords: CVD,diabetes,nephropathy,primary prevention,statin,Endocrinology, Diabetes and Metabolism,Cardiology and Cardiovascular Medicine
Full Text Link: http://cardiab. ... 2933-016-0463-9
Related URLs: http://www.scop ... tnerID=8YFLogxK (Scopus URL)
Published Date: 2016-10-13
Authors: Sasso, Ferdinando Carlo
Lascar, Nadia ( 0000-0001-9997-366X)
Ascione, Antonella
Carbonara, Ornella
de Nicola, Luca
Minutolo, Roberto
Salvatore, Teresa
Rizzo, Maria Rosaria
Cirillo, Plinio
Paolisso, Giuseppe
Marfella, Raffaele
, on behalf of NID-2 study group

Download

[img]

Version: Published Version

License: Creative Commons Attribution


Export / Share Citation


Statistics

Additional statistics for this record